Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1060028018779340 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing patient-centered care: a randomized study on G-CSF administration preferences in chemotherapy-induced neutropenia.
Support Care Cancer
October 2024
Rafael Institute, Integrative Medicine Center, Levallois-Perret, France.
Article Synopsis
- The study aimed to compare patient preferences for administering pegfilgrastim, a medication used to prevent chemotherapy-induced neutropenia, via prefilled syringe versus pen device among cancer patients at the Rafael Institute in France.
- In the trial involving 150 patients, results showed a significant preference for the pen device, with participants reporting lower pain levels and more positive emotions compared to the syringe, although satisfaction with nursing care was higher with the syringe.
- Overall, the findings highlighted a stronger preference for using the pen device for administration, which can help shape clinical practices and enhance patient-centered care.
A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer.
BMC Cancer
September 2024
Department of Breast Surgery, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, China.
Article Synopsis
- F-627 (efbemalenograstim alfa) is a new long-acting G-CSF designed to reduce neutropenia in patients undergoing chemotherapy, and this study compared its efficacy and safety against the standard treatment, filgrastim.
- In a multicenter, randomized trial with 239 patients, participants received either a single injection of F-627 or daily injections of filgrastim after chemotherapy with epirubicin and cyclophosphamide, focusing on the duration of severe neutropenia as the primary endpoint.
- Results showed that both treatments had similar effects on the duration of severe neutropenia, with F-627 being well tolerated and possibly offering some advantages in terms of a lower incidence and shorter
Filgrastim Use in the Treatment of Azathioprine-Induced Myelosuppression Toxicity After Prescription Error in the Feline.
J Am Anim Hosp Assoc
May 2024
From Foxboro Animal Hospital, Foxboro, MA.
Only one report on the successful use of filgrastim (granulocyte colony-stimulating factor) in cats for severe neutropenia following azathioprine toxicity exists. Here, we report on a case in which a cat was prescribed methimazole but the medication was filled incorrectly with azathioprine tablets and the prescription label indicated a methimazole dosing regimen that was administered for three days before recognition of the error. On presentation, the cat's physical examinations were consistent with previous examinations before ingestion of azathioprine.
View Article and Find Full Text PDFA Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants.
Adv Ther
March 2024
Coherus BioSciences, Inc., 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Introduction: To help prevent febrile neutropenia, pegfilgrastim-cbqv (UDENYCA; Coherus BioSciences), a pegfilgrastim (NEULASTA; Amgen) biosimilar, is administered 24-96 h after myelosuppressive chemotherapy. Delivery of pegfilgrastim-cbqv using an on-body injector (OBI) provides an alternative method of administration, affording options in drug delivery. This study aimed to establish pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence and assess the safety of pegfilgrastim-cbqv administered using an OBI compared with a prefilled syringe (PFS).
View Article and Find Full Text PDFEfficacy and safety of pegfilgrastim biosimilar MD-110 in patients with breast cancer receiving chemotherapy: Single-arm phase III.
Cancer Med
October 2023
Department of Breast Surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Article Synopsis
- Pegfilgrastim, a granulocyte-colony stimulating factor, is used to reduce the risk of febrile neutropenia during chemotherapy, and its biosimilar, MD-110, was tested for safety and efficacy in early-stage breast cancer patients undergoing chemotherapy.
- In a study with 101 participants receiving docetaxel and cyclophosphamide, the mean duration of severe neutropenia was only 0.2 days, significantly lower than the safety threshold.
- Common side effects included alopecia, constipation, and malaise, but MD-110 showed no additional safety issues compared to the original pegfilgrastim.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!